Alzheon is a biopharmaceutical startup based in Framingham, MA, that focuses on developing treatments for Alzheimer's disease. Founded in 2013 by Martin Tolar, MD, PhD, the company is currently testing ALZ-801, an oral anti-amyloid treatment, which is the only one of its kind in Phase 3 testing. Anti-amyloid treatments aim to slow or stop the progression of Alzheimer's by targeting and reducing amyloid plaques, abnormal clumps in the brain associated with the disease.

Alzheon's business model revolves around the research, development, and commercialization of this drug. The company's primary clients are patients with Alzheimer's, particularly those with two copies of the APOE4 gene, who are at the highest risk of developing the disease. The company plans to expand its treatment to patients with only one copy of the APOE4 gene in the future, and ultimately aims to prevent the onset of Alzheimer's disease.

Alzheon's revenue will primarily come from the sales of ALZ-801 once it is approved and launched commercially, which is projected to happen in 2025. The company's approach to precision medicine, which involves tailoring treatments to individual patients based on their genetic makeup, sets it apart in the market.

Keywords: Alzheimer's disease, biopharmaceutical, ALZ-801, anti-amyloid treatment, APOE4 gene, precision medicine, drug development, oral treatment, disease-modifying treatment, commercialization.